Targeting histone deacetylases for the treatment of Huntington's disease.
Huntington's disease is a debilitating neurodegenerative condition with significant burdens on both patient and healthcare costs. Despite the identification of the causative element, an expanded toxic polyglutamine tract in the mutant Huntingtin protein, treatment options for patients with this disease remain limited. In the following review I assess the current evidence suggesting that a family of important regulatory proteins known as histone deacetylases may be an important therapeutic target in the treatment of this disease.
Gray
Steven G
SG
Translational Cancer Research Group, Department of Clinical Medicine, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James's Hospital, James's Street, Dublin, Ireland. sgray@stjames.ie
D000818:Animals; D004195:Disease Models, Animal; D004721:Endoplasmic Reticulum / Q000201:enzymology / Q000502:physiology; D015870:Gene Expression; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006655:Histone Deacetylases / Q000502:physiology*; D006657:Histones / Q000235:genetics; D006801:Humans; D006816:Huntington Disease / Q000139:chemically induced / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D025801:Ubiquitin / Q000502:physiology
D056572:Histone Deacetylase Inhibitors; D006657:Histones; D025801:Ubiquitin; D006655:Histone Deacetylases